QED Therapeutics Stock
Precision medicine for FGFR-driven disorders
Sign up today and learn more about QED Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About QED Therapeutics Stock
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Investors
BridgeBio
Funding History
| January 2018 | $65.0M |
|---|
Management
President
Neil Kumar
Chief Revenue Officer
Curtis Scribner
Press
thepharmaletter - Apr, 7 2024
BridgeBio out-licenses infigratinib in Japanfinance - Mar, 2 2024
BridgeBio sells partial rights to dwarfism drug for $100Mbioworld - Mar, 2 2024
Kyowa pays $100M up front for Bridgebio's infigratinib in Japanfiercepharma - Mar, 2 2024
For $100M, BridgeBio partners with Kyowa Kirin on infigratinibEquityZen Recognized As:
